Edgewise Therapeutics Inc

NASDAQ:EWTX  
8.52
+0.25 (+3.02%)
Earnings Announcements

Edgewise Therapeutics Announces Positive 2-Month Interim Results From The Arch Open Label Study Of Edg-5506 In Adults With Becker Muscular Dystrophy (Bmd)

Published: 06/20/2022 12:58 GMT
Edgewise Therapeutics Inc (EWTX) - Edgewise Therapeutics Announces Positive 2-month Interim Results From the Arch Open Label Study of Edg-5506 in Adults With Becker Muscular Dystrophy (bmd).
Edgewise Therapeutics Inc - Edg-5506 Treatment Significantly Lowered Muscle Damage Biomarkers in Adults With Bmd.
Edgewise - Bmd Patients Were More Active During 2 Months of Dosing With Edg-5506 Relative to Activity Measured in Bmd Patients in Phase 1 Study.
Edgewise Therapeutics Inc - Edg-5506 Was Well Tolerated With No Serious Adverse Events Observed.
Revenue is expected to be $0 Million
Adjusted EPS is expected to be -$0.33

Next Quarter Revenue Guidance is expected to be $0 Million
Next Quarter EPS Guidance is expected to be -$0.37

More details on our Analysts Page.